

Table 4. Summary of Natural History Study Mechanistic Samples for Participants that develop T1D at some point over Baseline or Follow-up  
 (Complete Collection/Visit Hx Required\*)

P2 (n=112); P3:6m (n=48); P3:12m (n=23); P3:18m (n=11) P3:24m (n=6); P3:30m (n=4); P3:36m (n=2)

Collection Phase*	Sample Type**	No. Subjects (% Row Total): <25%	No. Subjects (% Row Total): >=25%	No. Subjects (% Row Total): >=50%	Risk Missing	Total No. Subjects Submitting Sample (%)
Baseline	DNA	1 (1.5)	3 (4.4)	61 (89.7)	3 (4.4)	68 (60.7)
	HLA	4 (3.7)	3 (2.8)	94 (87.9)	6 (5.6)	107 (95.5)
	RNA	2 (3.4)	3 (5.2)	50 (86.2)	3 (5.2)	58 (51.8)
	PLASMA	1 (1.9)	3 (5.6)	47 (87.0)	3 (5.6)	54 (48.2)
	SERUM	2 (3.8)	3 (5.7)	45 (84.9)	3 (5.7)	53 (47.3)
	PBMC	1 (1.9)	3 (5.7)	46 (86.8)	3 (5.7)	53 (47.3)
Follow-up (6m)	RNA	2 (7.4)	2 (7.4)	22 (81.5)	1 (3.7)	27 (56.3)
	PLASMA	2 (7.7)	2 (7.7)	21 (80.8)	1 (3.8)	26 (54.2)
	SERUM	2 (8.0)	2 (8.0)	20 (80.0)	1 (4.0)	25 (52.1)
	PBMC	2 (8.0)	2 (8.0)	20 (80.0)	1 (4.0)	25 (52.1)
Follow-up (12m)	RNA	2 (14.3)	2 (14.3)	10 (71.4)	. (.)	14 (60.9)
	PLASMA	2 (13.3)	2 (13.3)	11 (73.3)	. (.)	15 (65.2)
	SERUM	2 (13.3)	2 (13.3)	11 (73.3)	. (.)	15 (65.2)
	PBMC	2 (13.3)	2 (13.3)	11 (73.3)	. (.)	15 (65.2)
Follow-up (18m)	RNA	1 (12.5)	1 (12.5)	6 (75.0)	. (.)	8 (72.7)
	PLASMA	1 (14.3)	1 (14.3)	5 (71.4)	. (.)	7 (63.6)
	SERUM	1 (14.3)	1 (14.3)	5 (71.4)	. (.)	7 (63.6)
	PBMC	1 (16.7)	1 (16.7)	4 (66.7)	. (.)	6 (54.5)
Follow-up (24m)	RNA	1 (16.7)	1 (16.7)	4 (66.7)	. (.)	6 (100.0)
	PLASMA	1 (16.7)	1 (16.7)	4 (66.7)	. (.)	6 (100.0)
	SERUM	1 (20.0)	1 (20.0)	3 (60.0)	. (.)	5 (83.3)
	PBMC	1 (16.7)	1 (16.7)	4 (66.7)	. (.)	6 (100.0)
Follow-up (30m)	RNA	. (.)	1 (33.3)	2 (66.7)	. (.)	3 (75.0)
	PLASMA	. (.)	1 (33.3)	2 (66.7)	. (.)	3 (75.0)
	SERUM	. (.)	1 (33.3)	2 (66.7)	. (.)	3 (75.0)
	PBMC	. (.)	1 (33.3)	2 (66.7)	. (.)	3 (75.0)
Follow-up (36m)	RNA	. (.)	1 (50.0)	1 (50.0)	. (.)	2 (100.0)
	PLASMA	. (.)	1 (50.0)	1 (50.0)	. (.)	2 (100.0)
	SERUM	. (.)	1 (50.0)	1 (50.0)	. (.)	2 (100.0)
	PBMC	. (.)	1 (50.0)	1 (50.0)	. (.)	2 (100.0)

\* A subject enumerated in any Phase 3 visit is required to have had a Baseline (Phase 2) visit, as well as have completed "all" P3 visits preceding their latest P3 visit.

\*\* All DNA samples collected -- across all visits herein (Baseline and any Phase 3 follow-up) -- are presented at Baseline. Note that a subject should have only provided one DNA sample, although it is possible multiple were provided.